50 results on '"Cucci, Marie Angele"'
Search Results
2. Glutathione-responsive cyclodextrin-nanosponges as drug delivery systems for doxorubicin: Evaluation of toxicity and transport mechanisms in the liver
3. Ailanthone increases oxidative stress in CDDP-resistant ovarian and bladder cancer cells by inhibiting of Nrf2 and YAP expression through a post-translational mechanism
4. Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells
5. Contributors
6. Nrf2, YAP, antioxidant potential, and cancer
7. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
8. Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells
9. Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle
10. Surface Functionalised Parenteral Nanoemulsions for Active and Homotypic Targeting to Melanoma.
11. Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
12. Chapter 15 - Nrf2, YAP, antioxidant potential, and cancer
13. Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role
14. The Potential Therapeutic Target Nrf2 in Childhood Brain Tumors
15. Lipid Peroxidation-Derived Aldehydes, 4-Hydroxynonenal and Malondialdehyde in Aging-Related Disorders
16. How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study
17. T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials
18. Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
19. T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta
20. Is the combination of different treatment responseindicators useful to identify patients with a sub-optimal response to interferon beta?
21. MRNA levels of cytokines, chemokines and chemokine receptors as indicator of treatment response in Multiple Sclerosis patients treated with interferon-beta 1b
22. Indicators of treatment response to interferon beta in ms. mxa protein, il-10 mrna or mri?
23. A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
24. A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
25. Using biological (mxa protein or il-10 mrna level) or mri indicators for assessing treatment response to interferon-beta
26. Interferon beta-1b 500 mcg every-other-day, subcutaneously in ms patients. Tolerability, clinical and mri results after one year of treatment
27. Interferon beta-1b 500 mcg every-other-day in ms patients. Clinical and mri results
28. Looking for treatment response indicator. real- time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors in Multiple Sclerosis patients treated with ifn beta 1b: correlation with mri response
29. To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved
30. Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a
31. Mxa protein in ms patients treated with different doses of ifn beta-1b (the optims study): correlation with treatment response, ifn beta dose, and neutralizing antibodies (nab)occurrence
32. Mxa protein: correlation with magnetic resonance imaging response in relapsing-remitting multiple sclerosis patients treated with two different ifn beta doses
33. Real-time rt-pcr determination of mrna levels of cytokine, chemokine and chemokine receptors, in patients treated with ifn beta 1b: correlation with mri response and evaluation of a prognostic marker in ms
34. Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial
35. Mxa protein, interleukin-10 and neutralising antibody in MS patients treated with different doses of Interferon-Beta-1b
36. Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a
37. A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study
38. Mxa protein, interleukin-10 (il-10) and neutralizing antibody (nab) in relapsing- remitting (rr) multiple sclerosis (ms) patients treated with different doses of inteferon (ifn) beta- 1b
39. IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study)
40. Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD)
41. MX protein and neutralizing interferon antibodies in relapsing remitting multiple sclerosis patients treated with interferon beta-1b: correlation with clinical and mri efficacy
42. Secondary progressive (sp) ms: immunological effects of intravenous immunoglobuln g (ivig) therapy
43. Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study
44. Mitoxantrone safety in secondary progressive Multiple Sclerosis patients
45. La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b
46. NAB titre in patients treated with different doses of ifn beta-1b: preliminary results from the optims study
47. Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients
48. Long-term evaluation of safety and efficacy of mitoxantrone therapy in secondary progressive Multiple Sclerosis patients
49. Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients
50. Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.